Long-Term Health Effects of Peptides: The Evidence So Far

Why the answer depends on the peptide

"Peptides" covers compounds that share little beyond being short chains of amino acids. A growth hormone secretagogue raises hormone levels across the whole body. BPC-157 is studied mostly for local tissue repair. Semaglutide and tirzepatide are prescription medicines with large trial programs behind them. Their long-term risks differ, and so does the quality of the evidence.

No study has followed people using research-grade peptides for years. What exists is a patchwork of short human trials, drug labels, animal studies, hormone epidemiology and user reports. This page sorts the known risks by class and says what kind of evidence each one rests on, with links to articles that go deeper.

Growth hormone secretagogues

This group includes growth hormone-releasing hormone (GHRH) analogs such as CJC-1295 and tesamorelin, plus growth hormone-releasing peptides (GHRPs) and ghrelin mimetics such as ipamorelin, GHRP-2 and MK-677 (ibutamoren). (MK-677 is an oral small molecule, not a peptide, but it's usually grouped with them.) All of them push the pituitary to release more of the body's own growth hormone (GH), and the liver responds by making more IGF-1. In a 2006 study in healthy adults, one injection of CJC-1295 raised IGF-1 1.5- to 3-fold for 9 to 11 days. Most long-term questions come back to these two hormones.

Glucose and insulin sensitivity

The clearest human signal is metabolic. In a two-year randomized trial in 65 healthy adults aged 60 to 81, MK-677 at 25 mg a day raised GH and IGF-1 into the young-adult range and added about 1.1 kg of fat-free mass. Fasting glucose rose by an average of 5 mg/dL and insulin sensitivity fell. Strength and function didn't improve. LDL cholesterol dropped slightly while cortisol rose, so the blood-chemistry effects weren't uniformly good or bad.

Tesamorelin, the only compound in this group currently FDA-approved, carries a glucose warning. In the trials behind Egrifta, 5% of patients on the drug reached an HbA1c of 6.5% or higher by week 26, against 1% on placebo; the label calls this an increased risk of developing diabetes. It also reports IGF-1 more than 2 standard deviations above normal in 47% of patients at 26 weeks and says the effects of prolonged IGF-1 elevation are unknown.

User reports point the same way: raised fasting glucose and water retention come up often in community threads about tesamorelin and CJC-1295 with ipamorelin.

Heart signals and deaths in trials

Several human trials in this class were stopped early or turned up safety findings:

• MK-677: a Phase IIb trial in 123 older adults recovering from hip fracture (25 mg a day) was ended early because of a congestive heart failure signal in a small number of patients. Whether that applies to younger, healthy users is disputed.
• CJC-1295: a Phase 2 trial in HIV lipodystrophy was terminated after a participant had a fatal heart attack 2 hours after the 11th weekly dose. The attending physician blamed undiagnosed coronary artery disease. The data are unpublished; FDA described the case in its December 2024 review.
• Ipamorelin: a Phase 2 trial of IV ipamorelin after abdominal surgery missed its primary endpoint. The ipamorelin group had more high blood sugar and low potassium than placebo, and 2 people in that group died; FDA reviewers said causality was unclear.

FDA also lists increased heart rate and a systemic vasodilatory reaction among serious adverse events linked to CJC-1295. None of this proves these compounds damage the heart, but there's no basis for calling the class heart-protective, as some vendor and forum copy does.

IGF-1 and cancer risk

The longer-term worry is cancer. IGF-1 tells cells to grow and resist programmed cell death, which helps muscle and could also help a precancerous lesion. A 2004 meta-analysis in The Lancet pooled 21 studies with 3,609 cancer cases. People with IGF-1 at the 75th percentile had higher odds of prostate cancer (odds ratio about 1.5) and premenopausal breast cancer (about 1.65) than people at the 25th percentile. The authors called the associations modest.

That's observational data about people's natural IGF-1 levels, not a trial of secretagogues. Nobody has measured cancer rates in long-term users, and the trials above were too short to detect a difference. The tesamorelin label rules out use in patients with active cancer because it raises GH, a known growth factor. Many users cycle these compounds on and off partly with cancer risk in mind; whether that helps hasn't been tested. Our article on peptide cycling strategies covers the schedules users describe.

BPC-157 and TB-500

Users often combine these two, but they are different molecules with different evidence. Neither raises GH or IGF-1 the way the secretagogues do.

What the human data cover

As of October 2026, the human evidence for BPC-157 is three small uncontrolled pilot studies. In a retrospective series, 14 of 16 people with knee pain reported relief after injections of BPC-157 alone or combined with thymosin beta-4. A second pilot gave bladder instillations to 12 patients with interstitial cystitis. The third infused 10 mg and then 20 mg IV into 2 adults and found no change in the blood markers tested. None reported adverse events.

A 2025 systematic review in HSS Journal found 35 preclinical studies, 1 clinical study and no clinical safety data. Animal studies found no lethal dose, but none tracked adverse events beyond 6 weeks. That's why the site rates BPC-157's evidence as emerging. As of October 2026, a University of Arkansas Phase 1 trial in rotator cuff repair (about 30 participants) is not yet recruiting; its registry record says BPC-157 "has not undergone formal human clinical trials."

Users commonly report 250-500 mcg a day by subcutaneous injection. Vendor and community guides describe courses of 4-12 weeks, a duration no human study has tested. Users also report fatigue or low mood early on, and many say they noticed no benefit.

TB-500 has even less behind it. It's a synthetic 7-amino-acid fragment of thymosin beta-4 (sequence LKKTETQ), not the full 43-amino-acid protein. As of October 2026, FDA says it has not identified any human exposure data for the fragment. Human trials of thymosin beta-4 used the full protein, mostly as eye drops or gels (a Phase 3 eye-drop trial, SEER-2, is still listed on ClinicalTrials.gov), and they say little about injected TB-500. The site rates TB-500 as preliminary. Many users aren't sure whether their vials hold the fragment or the full protein.

The angiogenesis question

In animal studies, BPC-157 promotes angiogenesis (new blood vessel growth), partly through VEGF receptor signaling. Tumors depend on new blood vessels too, so cancer promotion is a fair theoretical concern. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine also notes the opposite finding: in cell and animal work, BPC-157 inhibited VEGF-driven tumor growth. Neither result has been tested in people, and no one has followed human users long enough to see cancer outcomes. The long-term risk of BPC-157 isn't known to be low or high; it hasn't been measured.

GLP-1 medicines

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are prescription medicines tested in trials of 64 to 72 weeks, so their risks are the best documented on this page. As of October 2026, both labels list stomach and bowel effects such as nausea and diarrhea as the most common side effects. Both warn about acute pancreatitis and gallbladder disease, and both carry a boxed warning for thyroid C-cell tumors seen in rodents, with the human risk unknown. Both also warn about diabetic retinopathy complications in type 2 diabetes; the tirzepatide label added this in August 2026.

These findings apply to the approved products. Research-use vials sold under the same names aren't made or tested the same way.

Risks that come with the vial

Products sold "for research use only" aren't made under drug manufacturing rules, so the dose and purity in a vial may not match its label. On its compounding safety-risk page (updated April 2026), FDA cites peptide-related impurities and immunogenicity (the risk of an immune reaction to the product) as concerns for several of these compounds, including TB-500. That risk sits on top of whatever the molecule itself does, and it makes user reports harder to interpret. For sale and sport-testing rules, see our guide to peptides and the law.

How the classes compare

For how these compare with anabolic steroids, see peptides vs. steroids on long-term health.

What we still don't know

• Whether years of secretagogue use change cancer rates in healthy adults. No study has followed users long enough to tell.
• Whether the glucose changes seen with MK-677 and tesamorelin fully reverse after people stop.
• Whether BPC-157 is safe beyond 6 weeks in any species, let alone in people.
• Whether injected TB-500 does anything in humans, good or bad.

Lab tests can catch some effects early, such as rising glucose or IGF-1; monitoring and safety protocols covers the markers commonly tracked. Mental health effects are covered in the psychological side of peptide use.